aTYR PHARMA INC Debt Securities, Available-for-sale, Current
aTYR PHARMA INC (ATYR) had Debt Securities, Available-for-sale, Current of $41.26 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2026-08-07
- 2026-06-30: Debt Securities, Available-for-sale, Current $41.26M.
- 2026-03-31: Debt Securities, Available-for-sale, Current $56.51M.
- 2025-12-31: Debt Securities, Available-for-sale, Current $67.94M.
- 2025-09-30: Debt Securities, Available-for-sale, Current $84.05M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2026-06-30 | $41.26M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $56.51M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $67.94M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $84.05M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $63.13M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $65.99M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $61.07M 10-K · filed 2026-03-05 |
| 2024-09-30 | $54.53M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $71.68M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $77.69M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $75.62M 10-K · filed 2025-03-13 |
| 2023-09-30 | $92.34M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $96.27M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $93.69M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $56.16M 10-K · filed 2024-03-14 |
| 2022-09-30 | $59.02M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $80.07M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $90.34M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $105.58M 10-K · filed 2023-03-14 |
| 2021-09-30 | $56.61M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $41.87M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $38.05M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $14.74M 10-K · filed 2022-03-15 |
| 2020-09-30 | $18.00M 10-Q · filed 2020-11-13 |
| 2020-06-30 | $19.80M 10-Q · filed 2020-08-13 |
| 2020-03-31 | $10.38M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $21.93M 10-K · filed 2021-03-24 |
| 2019-09-30 | $20.72M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $27.89M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $30.05M 10-Q · filed 2019-05-14 |
| 2018-12-31 | $26.58M 10-K · filed 2020-03-26 |
| 2018-09-30 | $24.41M 10-Q · filed 2018-11-14 |
| 2018-06-30 | $45.06M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $52.16M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $64.03M 10-K · filed 2019-03-26 |
| 2017-09-30 | $60.62M 10-Q · filed 2017-11-14 |
| 2017-06-30 | $21.31M 10-Q · filed 2017-08-14 |
| 2017-03-31 | $33.03M 10-Q · filed 2017-05-11 |
| 2016-12-31 | $33.76M 10-K · filed 2018-03-20 |
| 2016-09-30 | $36.20M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $40.73M 10-Q · filed 2016-08-10 |
| 2015-12-31 | $42.51M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |